Articles related to RESEARCH & CLINICAL TRIALS

The Epitomee capsule, a novel ingestible device for weight management, has shown promising results in clinical trials, with 55.5% of users losing at least 5% of their baseline body weight at 24 weeks.

Sanbexin’s sublingual formulation offers a potential paradigm shift in acute ischemic stroke treatment, enabling flexible administration outside traditional hospital settings.

Chemotherapy-free regimens for Ph+ ALL have shown complete response rates of 94-100% with minimal toxicity, potentially eliminating the need for stem cell transplant in many patients.

A new network meta-analysis reveals that high-dose psilocybin may be as effective as escitalopram for treating depressive symptoms, with a standardized mean difference of 0.31 compared to placebo in antidepressant trials.

Recent studies suggest that ALS may begin to develop shortly after conception, taking years or decades before symptoms appear, highlighting the importance of early intervention and lifestyle modifications.

Osimertinib significantly improved progression-free survival in patients with unresectable stage III EGFR-mutant NSCLC after chemoradiotherapy, with a hazard ratio of 0.16 compared to placebo.